- ►mcgill.ca [PDF] M Pollak - Nat Rev Cancer, 2008 - canadiancpd.medscape.com Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy metabolism
and growth. There is now considerable evidence that these hormones and the signal transduction
networks they regulate have important roles in neoplasia. Epidermiological, clinical and ... Cited by 46 - Related articles - All 10 versions
- ►abbmcertification.org [PDF] MM Swarbrick, PJ Havel - Metabolic Syndrome and Related Disorders, 2008 - liebertonline.com Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and
atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations
are inversely proportional to adiposity, and low adiponectin concentrations predict the ... Cited by 25 - Related articles - BL Direct - All 4 versions
- ►annals.org R Nass, SS Pezzoli, MC Oliveri, JT Patrie, … - Annals of internal …, 2008 - Am Coll Physicians Background: Growth hormone secretion and muscle mass decline from midpuberty throughout
life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline
of growth hormone in the development of sarcopenia is one of many factors, and its ... Cited by 22 - Related articles - All 10 versions
- ►endojournals.org Y Sun, NF Butte, JM Garcia, RG Smith - Endocrinology, 2008 - Endocrine Soc Ghrelin and the ghrelin receptor (GH secretagogue receptor, GHS-R), are believed to have important
roles in energy homeostasis. We describe results from the first studies to be conducted in congenic
(N10) adult ghrelin –/– and Ghsr –/– mice under conditions of both positive (high-fat diet) ... Cited by 13 - Related articles - BL Direct - All 11 versions
- ►endojournals.org C Nielsen, LC Gormsen, N Jessen, SB … - Journal of Clinical …, 2008 - Endocrine Soc Intervention: GH was administered as a bolus (n = 8) and constant infusion (n = 8). The bolus
study included three arms: 1) control (saline), 2) GH (0.5 mg iv), and 3) GH blockade (pegvisomant
30 mg sc), each combined with a hyperinsulinemic glucose clamp. The infusion study ... Cited by 13 - Related articles - All 4 versions
- ►endocrinology-journals.org RP Rhoads, JW Kim, ME Van Amburgh, RA … - Journal of …, 2007 - Soc Endocrinology Dairy cows enter a period of energy insufficiency after parturition. In liver, this energy deficit leads
to reduced expression of the liver-specific GH receptor transcript (GHR1A) and decreased GHR
abundance. As a consequence, hepatic processes stimulated by GH, such as IGF-I ... Cited by 9 - Related articles - BL Direct - All 2 versions
DE Berryman, JS Christiansen, G Johannsson, MO … - Growth Hormone & IGF …, 2008 - Elsevier Animal models are fundamentally important in our quest to understand the genetic,
epigenetic, and environmental factors that contribute to human aging. In comparison to
humans, relatively short-lived mammals are useful models as they allow for rapid ... Cited by 9 - Related articles - All 2 versions
N Moller, JOL Jorgensen - Endocrine Reviews, 2009 - Endocrine Soc In evolutionary terms, GH and intracellular STAT 5 signaling is a very old regulatory system. Whereas
insulin dominates periprandially, GH may be viewed as the primary anabolic hormone during
stress and fasting. GH exerts anabolic effects directly and through stimulation of IGF-I, ... Cited by 8 - Related articles - All 4 versions
- ►cell.com K Kok, B Geering, B Vanhaesebroeck - Trends in Biochemical Sciences, 2009 - Elsevier Both the biology and the therapeutic potential of the phosphoinositide 3-kinase (PI3K) signalling
axis have been the subject of intense investigation; however, little is known about the regulation
of PI3K expression. Emerging evidence indicates that PI3K levels change in response to ... Cited by 4 - Related articles - All 6 versions
A Gualberto, M Pollak - Oncogene, 2009 - mcgill.ca Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective in
cancer treatment has been accumulating for almost two decades. Efforts to develop drugs began
in the late 1990s, and initial data from clinical trials were reported in 2006. The biological ... Cited by 4 - Related articles - View as HTML - All 4 versions
